Comparison of low-dose liraglutide use versus other GLP-1 receptor agonists in patients without type 2 diabetes.

CONCLUSIONS: In patients without a T2D diagnosis, LD-L use was significantly greater than that with other GLP-1 RAs within 6 months after approval of HD-L; differences persisted until the end of the study. Increased payer scrutiny of appropriate LD-L use is warranted.
PMID: 29693362 [PubMed - in process]

Source: The American Journal of Managed Care - April 1, 2018 Category: Health Management Authors: Wittbrodt ET, Eudicone JM, Farahbakhshian S, McAdam-Marx C Tags: Am J Manag Care Source Type: research